CBD Co. Wants Counterclaims Nixed In Epidiolex Patent Row
By Sam Reisman · July 18, 2023, 3:58 PM EDT
British pharmaceutical firm GW Pharmaceuticals has urged a New Jersey federal judge to toss counterclaims lodged by InvaGen Pharmaceuticals in a patent dispute regarding GW's flagship CBD-derived epilepsy treatment Epidiolex....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login